Financial Call Details Revenue Growth and REC-4881 Clinical Results

Vicki Goodman and Ben Taylor participated in a financial call that reported $18.6 million in revenue for the third quarter, an increase from $5.2 million in the prior year, driven by milestone payments from collaboration partners. The company reported a net loss of $119 million for the quarter, while maintaining a pro forma cash position of approximately $748.7 million, which includes $187.2 million in net proceeds from an October offering. Clinical results for REC-4881 showed that 87% of evaluable patients in the TUPELO study experienced a reduction in total polyp burden after 12 weeks of treatment.

The reported revenue increase and strong cash position reflect operational discipline and capital concentration, with management guiding cash operating expenses below $375 million for 2026. The positive clinical outcomes for REC-4881, including 85% durability of polyp burden reduction, support the company's pipeline and potential market viability.